<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-24</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-24</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>41</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹å•ç»†èƒæµ‹åºæ–¹æ³•RoCK and ROI å¢å¼ºè½¬å½•ç»„ä¿¡æ¯è·å–ï¼›ç©ºé—´ç»„å­¦æŠ€æœ¯Seq-Scope-Xçªç ´å…‰å­¦åˆ†è¾¨ç‡é™åˆ¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- <strong>ç–¾ç—…æœºåˆ¶æ¢ç´¢</strong>ï¼šèšç„¦ç³–å°¿ç—…è‚¾ç—…ã€é˜¿å°”èŒ¨æµ·é»˜ç—…ã€COVID-19ã€çš®è‚¤ç™Œã€å°ç»†èƒè‚ºç™Œã€è‘¡è„è†œé»‘è‰²ç˜¤è‚è½¬ç§»ã€ç™«ç—«ç­‰ç–¾ç—…çš„å…³é”®è°ƒæ§å› å­ä¸å¾®ç¯å¢ƒé‡å¡‘ã€‚<br />
- <strong>å…ç–«ç»†èƒåŠŸèƒ½è°ƒæ§</strong>ï¼šæ·±å…¥ç ”ç©¶CAR-Tç»†èƒåŠŸèƒ½ã€æ·‹å·´ç»†èƒé€‚åº”æ€§ç¼–ç¨‹ã€å•æ ¸ç»†èƒè¡¨å‹ä¸å…ç–«è®°å¿†å½¢æˆã€‚<br />
- <strong>ä»£è°¢ä¸è¡¨è§‚é—ä¼ </strong>ï¼šé˜æ˜èƒ†å›ºé†‡ä»£è°¢ã€Î²ç»†èƒåŠŸèƒ½ã€èƒ½é‡æ„ŸçŸ¥åˆ†å­åœ¨ç–¾ç—…ä¸­çš„ä½œç”¨ï¼Œä»¥åŠä»£è°¢å¯¹è¡¨è§‚é—ä¼ çš„é‡å¡‘ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>å•ç»†èƒå¤šç»„å­¦</strong>ï¼šç»“åˆscRNA-seqä¸scATAC-seqç­‰æŠ€æœ¯ï¼Œè§£æç»†èƒå¼‚è´¨æ€§ä¸åŸºå› è°ƒæ§ã€‚<br />
- <strong>ç©ºé—´ç»„å­¦</strong>ï¼šå¼€å‘Seq-Scope-Xç­‰æŠ€æœ¯ï¼Œå®ç°é«˜åˆ†è¾¨ç‡çš„ç©ºé—´è½¬å½•ç»„åˆ†æã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹æŠ—ä½“æœ‰æœ›æ”»å…‹ä¸‰é˜´æ€§ä¹³è…ºç™Œï¼Œé•¿è¯»é•¿RNAæµ‹åºæŠ€æœ¯åœ¨æ—å¥‡ç»¼åˆå¾è¯Šæ–­æ–¹é¢å–å¾—çªç ´ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- é’ˆå¯¹ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„é¶å‘æ²»ç–—ç ”ç©¶<br />
- åˆ©ç”¨é•¿è¯»é•¿RNAæµ‹åºæŠ€æœ¯æ”¹è¿›æ—å¥‡ç»¼åˆå¾çš„åŸºå› è¯Šæ–­</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å‘ç°å¹¶éªŒè¯å¯é¶å‘è‚¿ç˜¤ç”Ÿé•¿ç›¸å…³è›‹ç™½çš„æ–°å‹å®éªŒæ€§æŠ—ä½“<br />
- åº”ç”¨é¶å‘é•¿è¯»é•¿RNAæµ‹åºæŠ€æœ¯ï¼Œæœ‰æ•ˆè¯†åˆ«è‡´ç—…æ€§å‰ªæ¥ç¼ºé™·ï¼Œå¹¶è§£å†³æ—å¥‡ç»¼åˆå¾ä¸­çš„ä¸ç¡®å®šå˜å¼‚ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (39æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE287840 RoCK å’Œ ROIï¼šä¸€ç§é€šè¿‡é¶å‘å¯Œé›†è½¬å½•æœ¬å’Œé¢„é€‰åŒºåŸŸç‰¹å¼‚æ€§æµ‹åºå¢å¼ºè½¬å½•ç»„ä¿¡æ¯çš„å•ç»†èƒ RNA æµ‹åºæ–¹æ³• IV</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cellã€transcriptomeã€enrichment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Giulia Moro ; Izaskun Mallona ; Malwine J Barz ; Lorenz Bastian ; Claudia D Baldus ; Mark D Robinson ; Erich Brunner ; Konrad BaslerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMany scRNAseq-based methods suffer from a high number of non-detects and a bias towards the 3' or 5' end of transcripts. We developed a method termed RoCK and ROI to address these two biases. RoCK and ROI leads to the enrichment of the transcriptome profile of cells with information on transcripts of interest<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287840" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE317266 èƒ½é‡æ„ŸçŸ¥åˆ†å­RORÎ³åœ¨ç³–å°¿ç—…è‚¾ç—…å’Œè¡°è€è¿‡ç¨‹ä¸­è°ƒèŠ‚èƒ†å›ºé†‡ä»£è°¢å’Œå…ç–«ä¿¡å·ä¼ å¯¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€agingã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAging is a major risk factor for diabetic kidney disease (DKD), with both conditions exhibiting similar renal pathology. We identify the energy-sensing molecule Retinoic acid-related orphan receptor Î³ (RORÎ³) as significantly downregulated in diabetic and aged kidneys. Tubule-specific RORÎ³ deficiency exacerbates kidney injury, whereas its overexpression protects. Mechanistically, RORÎ³ stabilizes insulin-induced gene 1 (INSIG1) by upregulating the deubiquitinase YOD1 and enhancing AMPK activity via CAB39, which together promote INSIG1 phosphorylation and subsequent stabilization. Stabilized INSIG1 potently blocks the ER-to-Golgi transport and activation of SREBP2 (cholesterol synthesis) and STING (inflammatory signaling). In diabetes, RORÎ³ itself is suppressed transcriptionally by CTCF and functionally by impaired AMPK/SIRT1 signaling, which hinders its activation. Importantly, administration of a RORÎ³ agonist or RORÎ³-enriched exosomes effectively alleviates diabetic kidney injury. Thus, RORÎ³ emerges as a key regulatory node that mitigates DKD and renal aging by co-regulating AMPK-mediated metabolic and STING-driven innate immune pathways through INSIG1 stabilization.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317266" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE297529 åˆ©ç”¨å•ç»†èƒå¤šç»„å­¦æµ‹åºå‘ç°ä¸ COVID-19 ä¸¥é‡ç¨‹åº¦ç›¸å…³çš„ç»å…¸å•æ ¸ç»†èƒè¡¨å‹ä¸­çš„å…³é”®è°ƒæ§å› å­</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmonocyteã€sequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Donggun Kim ; Sin Young Choi ; Eui Tae Kim ; Jihwan ParkSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensDysregulated immune responses often accompany severe COVID-19, but the underlying epigenetic mechanisms driving monocyte heterogeneity and disease progression remain poorly understood. Here, we applied single-cell multi-omics profiling to peripheral blood mononuclear cells from individuals across five COVID-19 severity stages. We identified two severity-associated classical monocyte subtypes-IL7R+ and CD163+-characterized by distinct transcriptional and epigenetic landscapes. Using constructing of gene regulatory network and in silico TF perturbations, we revealed ETS1 as a key driver of IL7R+ monocytes with T cell-like signaling features, and JDP2 as a repressor maintaining the pro-fibrotic, anti-inflammatory identity of CD163+ monocytes via suppression of AP-1 activity. These subtypes were enriched in moderate-to-critical stages and exhibited signaling pathways associated with tissue remodeling and immune suppression. Our findings define monocyte heterogeneity linked to COVID-19 severity and identify ETS1 and JDP2 as central regulators, offering insight into immune dysregulation and potential therapeutic targets for fibrosis and long-term sequelae.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297529" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE275131 æŠ‘åˆ¶ç¡¬è„‚é…°è¾…é…¶Aå»é¥±å’Œé…¶ï¼ˆSCDï¼‰å¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼ˆADï¼‰å°é¼ æ¨¡å‹ç©ºé—´è½¬å½•ç»„çš„å½±å“</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€spatialã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Audrey Hector ; BenoÃ®t Delignat-Lavaud ; Valerie MongrainSeries Type : OtherOrganism : Mus musculusHere, the effects of a stearoyl-CoA desaturase inhibitor (SCDi) on the mouse brain spatial transcriptome was investigated. More precisely, wild-type and 3xTg-AD female mice were infused in the brain left lateral ventricle with control (DMSO) or SCDi during 28 days (after the implantation of electrodes for electrocorticography and electromyography). Brains were sampled on the morning of Day 31 after the beginning of treatment, and immediately frozen. Brains were treated and libraries were prepared according to 10x Genomics protocols for Visium Spatial Gene Expression. Sequencing was conducted by Genome Quebec (Montreal, QC, Canada).<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275131" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE287857 LDHA é€šè¿‡ä»£è°¢è¡¨è§‚é—ä¼ é‡ç¼–ç¨‹è¯±å¯¼ç³–å°¿ç—…ä¸­çš„ Î² ç»†èƒå»åˆ†åŒ– [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€RNA-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xirui Li ; Haoqiang Gong ; Can Xiong ; Xinyue Huang ; Mei He ; Liangjun Sun ; Wenyue Yin ; Suyun Zou ; Min Sha ; Wanhua Guo ; Tijun Wu ; Qingguo Li ; Yaqin Zhang ; Fang ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAims/hypothesis Pancreatic Î² cell dedifferentiation underlies the reversible reduction in Î² cell mass and function in diabetes. Interventional targets and adjuvant therapies to prevent/reverse Î² cell dedifferentiation and transdifferentiation may provide evidence to support the effective treatment of diabetes, while the underlying molecular mechanism remains elusive. Methods LDHA expression and activity were analysed in islets obtained from humans with type 2 diabetes, hyperglycaemic db/db mice, and a high-fat diet (HFD)-induced mouse model of diabetes. The impact of LDHA inhibition on Î² cell function and identity was investigated in high-fat diet (HFD) feeding mice and db/db mice. ChIP-seq and RNA-seq were used to investigate the specific molecular mechanism underlying the effect of LDHA on the H3K9la enhancement and beta cell function under glucotoxic conditions. Results We demonstrated that inhibition of LDHA effectively preserved Î² cell identity, which not only delay disease progression in prediabetic stage, but also improve insulin output and glucose homeostasis in diabetic models. Mechanistically, the activation of LDHA led to a marked increase in histone H3 lysine 9 lactylation (H3K9la) in the promoter region of the Î² cells dedifferentiation markers Sox9, Hes1 and Aldh1a3, and facilitated their transcription, thereby triggering Î² cell dedifferentiation as well as impaired glucose homeostasis and Î² cell function in mice. Conclusions/interpretation We unraveled the role of lactate dehydrogenase A (LDHA)-mediated metabolic and epigenetic reprogramming in Î² cell dedifferentiation during diabetes development. This study suggests that LDHA inhibition could be a novel therapeutic strategy for diabetes treatment.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287857" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE284026 NR2F6 ç¼ºå¤±å¯æ¢å¤ CAR-T ç»†èƒåŠŸèƒ½å¹¶è¯±å¯¼å®ä½“ç˜¤ä¸­æŠ—åŸéç‰¹å¼‚æ€§å…ç–«è®°å¿†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€T cellã€antigen<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Dominik Humer ; Victoria Klepsch ; Dietmar Rieder ; Gottfried BaierSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusCARâ€‘T cell therapy is effective in hematologic malignancies but remains challenging in solid tumors owing to antigen heterogeneity and tumor microenvironmentâ€‘induced exhaustion. Here, gene editing of the nuclear receptor NR2F6 restores CARâ€‘T cell functionality, sustaining a TCF1âº progenitorâ€‘exhausted T cell phenotype, enhancing metabolic fitness, and preserving cytotoxic potency under chronic antigen exposure. In immunocompetent models, Nr2f6â€‘deficient CARâ€‘T cells suppress solid tumor growth and induce robust, polyclonal host antitumor responses, as shown by protection in tumor reâ€‘challenge experiments. Although infused CARâ€‘T cells disappear within 2 weeks, durable tumor control coincides with epitope spreading and secondary immune responses, likely via dendritic and other antigenâ€‘presenting cell reactivation. Protection against antigenâ€‘negative tumors and transferable immunity reveal a dual mode of direct cytotoxicity followed by durable immune reprogramming. This broadened host immunity may offset immune escape driven by antigen loss and tumor heterogeneity, establishing NR2F6 inhibition as a promising CARâ€‘T engineering strategy for durable, antigenâ€‘agnostic solidâ€‘tumor immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284026" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE308414 é€æ­¥è¡¨è§‚é—ä¼ ä¿¡å·æ•´åˆæ§åˆ¶ç»†èƒæ¯’æ€§æ·‹å·´ç»†èƒçš„é€‚åº”æ€§ç¼–ç¨‹ [ATAC-seq AP1æŠ‘åˆ¶å‰‚]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šATAC-seqã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Simon Grassmann ; Hyunu Kim ; Joseph SunSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusLymphocyte differentiation depends on activation via antigen and cytokines during the immune response to infection. How the timing and integration of these signals program the epigenetic and functional fate of these cells is not completely understood. In this study, we find that inflammatory cytokine signals received by innate and adaptive lymphocytes have a context-dependent role for immune memory formation. Without preceding and sufficient antigen receptor signaling, inflammatory cytokines drive terminal differentiation into short-lived effector cells. In contrast, sufficient antigen-receptor signaling redirects inflammatory cytokine signals to promote memory differentiation via cooperation of STAT and AP-1 transcription factors. By this crucial epigenetic mechanism, optimally equipped lymphocytes are selected for memory formation rather than a terminal effector cell fate. Whereas T cells are hardwired to be shielded from premature inflammatory signals, NK cells rely on coincidental early antigen receptor signaling for adaptive responses. Together, step-wise integration of antigen and cytokine signaling optimizes both effector and memory differentiation, allowing for promiscuous recruitment into the acute immune response while promoting avidity maturation in memory populations of both innate and adaptive lymphocytes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308414" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE304036 éä¾µå…¥æ€§è¡¨çš®å–æ ·ç”¨äºåŸºäºDNAç”²åŸºåŒ–çš„çš®è‚¤ç™Œè¡¨å‹é¢„æµ‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Manuel RodrÃ­guez-Paredes ; Yan Feng ; Oliver Gilliam ; Katrin Wegner ; GÃ¼nter Raddatz ; Elke GrÃ¶nniger ; Frank LykoSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensThe epidermis is uniquely exposed to the effects of environmental factors such as ultraviolet radiation, which induce progressive genetic and epigenetic modifications contributing to aging and the onset of keratinocyte carcinomas. DNA methylation is the best-characterized epigenetic modification and a valuable biomarker for assessing epidermal health. However, broad screening approaches have been hindered by the limited quantity and quality of the genomic DNA obtained from the epidermis and the resulting need for invasive sampling methods. Here we describe an integrated method that enables the non-invasive sampling of epidermal DNA for subsequent analysis by DNA methylation microarrays. This procedure combines a gel-based adhesive tape for keratinocyte collection, a robust gDNA extraction protocol and a curated selection of microarray probes optimized for low-input DNA conditions. Analysis of &gt;100 corresponding methylomes demonstrates that our approach can be used for both the training of epigenetic clocks capable of predicting epidermal age with high accuracy, as well as the investigation of various DNA methylation-based biomarkers relevant to keratinocyte cancer development. These findings underscore the potential of our method for broad and non-invasive skin health assessment and cancer prevention strategies.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304036" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE316934 é«˜è„‚é¥®é£Ÿåé‡ç”Ÿå‹å’ŒCamk2dé«“ç³»æ¡ä»¶æ€§æ•²é™¤å°é¼ eWATåŸºè´¨è¡€ç®¡ç»„åˆ†ç»†èƒçš„å•ç»†èƒRNAæµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yifan Tu ; Ke Sui ; Zheng Wang ; Jiawei Zhang ; Ying GuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusEpididymal white adipose tissue (eWAT) stromal vascular fraction (SVF) cells were profiled by 10x Genomics Chromium Single Cell 3â€² v1 scRNA-seq to characterize immune-cell states in diet-induced obesity. SVF cells were isolated by collagenase digestion, filtered, and processed when viability exceeded 85%. Libraries were sequenced on an Illumina NovaSeq 6000 (PE150). Reads were aligned to mm10 and geneâ€“cell count matrices were generated with Cell Ranger count v5.0.0 and aggregated across samples with Cell Ranger aggr. Downstream analyses were performed in Seurat v4.1.1 with QC filtering, ambient RNA correction (SoupX v1.3.0), doublet detection (DoubletFinder v2.0.2), batch correction (fastMNN), clustering/UMAP, and differential expression testing (MAST). Cell types were annotated using SingleR v1.4.1 and canonical markers; non-immune cells were excluded for immune-focused analyses. Additional analyses included pseudotime inference (Monocle2 v2.14.0) and cellâ€“cell communication analysis (CellChat v0.0.2).<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316934" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE287891 è½¬å½•å› å­ Traffic jam åè°ƒæœè‡åµå·¢ä¸­çš„ä½“ç»†èƒ piRNA é€šè·¯ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Azad Alizada ; Aline Martins ; Nolwenn MouniÃ©e ; Julia V Rodriguez Suarez ; Benjamin Bertin ; Nathalie Gueguen ; Vincent Mirouse ; Anna-Maria Papameletiou ; Austin J Rivera ; Nelson C Lau ; Abdou Akkouche ; StÃ©phanie Maupetit-Mehouas ; Gregory J Hannon ; Benjamin Czech Nicholson ; Emilie BrassetSeries Type : Expression profiling by high throughput sequencingOrganism : Drosophila melanogasterThe PIWI-interacting RNA (piRNA) pathway is essential for transposable element (TE) silencing in animal gonads. While the transcriptional regulation of piRNA pathway components in germ cells has been documented in mice and flies, their control in somatic cells of Drosophila ovaries remains unresolved. Here, we demonstrate that Traffic jam (Tj), the Drosophila orthologue of large Maf transcription factors in mammals, is a master regulator of the somatic piRNA pathway. Tj binds to regulatory regions of somatic piRNA factors and the major piRNA cluster flamenco, which carries a Tj-bound enhancer downstream of its promoter. Depletion of Tj in somatic follicle cells causes downregulation of piRNA factors, loss of flam expression and de-repression of gypsy-family TEs. We propose that the arms race between the host and TEs led to the co-evolution of promoters in piRNA pathway genes as well as TE regulatory regions that both rely on a shared transcription factor.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287891" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 29 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>é¶å‘é•¿è¯»é•¿RNAæµ‹åºæé«˜äº†æ—å¥‡ç»¼åˆå¾çš„è¯Šæ–­ç‡ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šTargeted long-read RNA sequencing reveals pathogenic splicing defects and resolves uncertain variants in Lynch syndrome, highlighting the clinical value of transcript-level analysis...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/targeted-long-read-rna-sequencing-improves-diagnosis-of-lynch-syndrome/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>è¿™ç§æ–°å‹æŠ—ä½“æˆ–è®¸èƒ½å¤Ÿé˜»æ­¢æœ€è‡´å‘½çš„ä¹³è…ºç™Œä¹‹ä¸€çš„å‘ç”Ÿã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šantibody<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of the disease. An experimental antibody targets a protein that fuels tumor growth and shuts down immune defenses, effectively turning the immune system back on. In early tests, the treatment slowed tumor growth, reduced lung metastases, and destroyed chemotherapy-resistant cancer cells.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260122074030.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>8</td>
</tr>
<tr>
<td>cancer</td>
<td>6</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>4</td>
</tr>
<tr>
<td>epigenetic</td>
<td>4</td>
</tr>
<tr>
<td>transcriptome</td>
<td>4</td>
</tr>
<tr>
<td>sequencing</td>
<td>3</td>
</tr>
<tr>
<td>methylation</td>
<td>3</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>scRNA</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>2</td>
</tr>
<tr>
<td>aging</td>
<td>2</td>
</tr>
<tr>
<td>metabolism</td>
<td>2</td>
</tr>
<tr>
<td>spatial</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>monocyte</td>
<td>1</td>
</tr>
<tr>
<td>TME</td>
<td>1</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>1</td>
</tr>
<tr>
<td>scATAC</td>
<td>1</td>
</tr>
<tr>
<td>regex:intestin(e</td>
<td>al)</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (29æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287858" target="_blank" rel="noopener noreferrer">GSE287858 LDHAé€šè¿‡ä»£è°¢è¡¨è§‚é—ä¼ é‡ç¼–ç¨‹è¯±å¯¼ç³–å°¿ç—…Î²ç»†èƒå»åˆ†åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287823" target="_blank" rel="noopener noreferrer">GSE287823 ä¸¤ç§è·å¾—æ€§ç™«ç—«å¤§é¼ æ¨¡å‹ä¸­åŸºå› è¡¨è¾¾å’Œç”²åŸºåŒ–å˜åŒ–çš„å…±æ€§ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317298" target="_blank" rel="noopener noreferrer">GSE317298 å¤šç»„å­¦åˆ†ææ­ç¤ºå¾®ç¯å¢ƒé‡å¡‘æ˜¯å±‹å°˜è¨è¯±å‘è‚ºç™Œè¿›å±•çš„å…³é”®é©±åŠ¨å› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309245" target="_blank" rel="noopener noreferrer">GSE309245 é€æ­¥ä¿¡å·æ•´åˆæ§åˆ¶æ·‹å·´ç»†èƒçš„é€‚åº”æ€§ç¼–ç¨‹ [bulkRNA-seq å’Œ ATAC-seq 6 å°æ—¶åˆºæ¿€]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308415" target="_blank" rel="noopener noreferrer">GSE308415 é€æ­¥è¡¨è§‚é—ä¼ ä¿¡å·æ•´åˆæ§åˆ¶ç»†èƒæ¯’æ€§æ·‹å·´ç»†èƒçš„é€‚åº”æ€§ç¼–ç¨‹ [CUT&amp;RUN STAT1 STAT5 cJun]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294461" target="_blank" rel="noopener noreferrer">GSE294461 æ¯”è¾ƒä¸¤ç§ä¸åŒç±»å‹è‚¿ç˜¤ï¼ˆB16/F10-BrM å’Œ H2030-BrMï¼‰è„‘è‚¿ç˜¤å¾®ç¯å¢ƒä¸­çš„ CD74+ ä¸ CD74- å°èƒ¶è´¨ç»†èƒ/å·¨å™¬ç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292377" target="_blank" rel="noopener noreferrer">GSE292377 é€æ­¥ä¿¡å·æ•´åˆæ§åˆ¶æ·‹å·´ç»†èƒçš„é€‚åº”æ€§ç¼–ç¨‹ [bulkRNA-seq å’Œ ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292296" target="_blank" rel="noopener noreferrer">GSE292296 é€æ­¥ä¿¡å·æ•´åˆæ§åˆ¶æ·‹å·´ç»†èƒçš„é€‚åº”æ€§ç¼–ç¨‹ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317349" target="_blank" rel="noopener noreferrer">GSE317349 GDF15 é‡ç¼–ç¨‹å¾®ç¯å¢ƒä»¥é©±åŠ¨è‘¡è„è†œé»‘è‰²ç´ ç˜¤è‚è½¬ç§»çš„å‘å±• [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317347" target="_blank" rel="noopener noreferrer">GSE317347 GDF15 é‡ç¼–ç¨‹å¾®ç¯å¢ƒä»¥é©±åŠ¨è‘¡è„è†œé»‘è‰²ç´ ç˜¤è‚è½¬ç§»çš„å‘å±• [bulk RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316978" target="_blank" rel="noopener noreferrer">GSE316978 ç±³ç´¢éœ‰ç´ æ”¹å˜ EWS::FLI1 DNA ç»“åˆå’Œ RNA èšåˆé…¶ II åŠ å·¥èƒ½åŠ›ä»¥æŠ‘åˆ¶æ–°ç”Ÿè½¬å½• [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316811" target="_blank" rel="noopener noreferrer">GSE316811 Seq-Scope-eXpanded (Seq-Scope-X): è¶…è¶Šå…‰å­¦åˆ†è¾¨ç‡çš„ç©ºé—´ç»„å­¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303770" target="_blank" rel="noopener noreferrer">GSE303770 ISL1ï¼šå°ç»†èƒè‚ºç™Œä¸­ä¸€ç§æ–°å‹ç¥ç»å†…åˆ†æ³Œäºšå‹é¢„æµ‹å¯¹é²æ¯”æ›¿å®šçš„æŒä¹…ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298610" target="_blank" rel="noopener noreferrer">GSE298610 ç»å…¸ BAF å¤åˆç‰©é€šè¿‡è¾…å› å­å¼•å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ¥è°ƒæ§é—´å……è´¨å¹²ç»†èƒå¾®ç¯å¢ƒç»„æˆå’Œå‘½è¿ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298609" target="_blank" rel="noopener noreferrer">GSE298609 ç»å…¸ BAF å¤åˆç‰©é€šè¿‡è¾…å› å­å¼•å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ¥è°ƒæ§é—´å……è´¨å¹²ç»†èƒå¾®ç¯å¢ƒç»„æˆå’Œå‘½è¿ [scATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298608" target="_blank" rel="noopener noreferrer">GSE298608 ç»å…¸ BAF å¤åˆç‰©é€šè¿‡è¾…å› å­å¼•å¯¼çš„æŸ“è‰²è´¨é‡å¡‘æ¥è°ƒæ§é—´å……è´¨å¹²ç»†èƒå¾®ç¯å¢ƒç»„æˆå’Œå‘½è¿ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281433" target="_blank" rel="noopener noreferrer">GSE281433 è´ç‰¹ç±»è¯ç‰©è‹¯æ‰è´ç‰¹å¯¹è…¹æ°´ä»‹å¯¼çš„ä¸Šçš®ç™Œç»†èƒè½¬å½•å˜åŒ–çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281415" target="_blank" rel="noopener noreferrer">GSE281415 åµå·¢ç™Œè…¹æ°´æš´éœ²å¯¹ä¸Šçš®ç™Œç»†èƒç³»çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317332" target="_blank" rel="noopener noreferrer">GSE317332 ç”¨äºæ¢æµ‹äººç±» iPSC è¡ç”Ÿè‚ é“ç±»å™¨å®˜å¯¹åŸºè´¨ä¿¡å·çš„è½¬å½•ååº”çš„å®Œæ•´å®šä¹‰æ–¹æ¡ˆå’ŒåŸºäº PEG çš„å¹³å°</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315629" target="_blank" rel="noopener noreferrer">GSE315629 å…¨åŸºå› ç»„é‰´å®š 786-O ç»†èƒä¸­ H4K12 ä¹³é…¸åŒ–å’Œ GR çš„è½¬å½•é¶ç‚¹ï¼ˆæ— è®ºæ˜¯å¦ç”¨åœ°å¡ç±³æ¾å¤„ç†ï¼‰ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315326" target="_blank" rel="noopener noreferrer">GSE315326 å…¨åŸºå› ç»„é‰´å®šé€æ˜ç»†èƒè‚¾ç»†èƒç™Œ (ccRCC) ç»†èƒä¸­ H4K12 ä¹³é…¸åŒ–çš„è½¬å½•é¶ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314501" target="_blank" rel="noopener noreferrer">GSE314501 Mettl18ç¼ºé™·èƒšèƒçš„ç»¼åˆè½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308156" target="_blank" rel="noopener noreferrer">GSE308156 CARM1ä»‹å¯¼çš„å¯Œå«æ¬¡é»„å˜Œå‘¤çš„å¤–æ³Œä½“ç”Ÿç‰©åˆæˆé‡å¡‘CD8+ Tç»†èƒçš„è‚Œè‹·ä»£è°¢å¹¶å‰Šå¼±å…¶æŠ—è‚¿ç˜¤èƒ½åŠ›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306334" target="_blank" rel="noopener noreferrer">GSE306334 é¶å‘KEAP1å¤±æ´»è‚ºç™Œä¸­çš„æ³›ç´ ä¿¡å·é€šè·¯è„†å¼±æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289768" target="_blank" rel="noopener noreferrer">GSE289768 è¡°è€é€šè¿‡æ¿€æ´»æ•´åˆåº”æ¿€ååº”ä¿ƒè¿›è½¬ç§» [RNA-Seq OE]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288033" target="_blank" rel="noopener noreferrer">GSE288033 é€šè¿‡æ•´åˆåŸºå› ç»„åˆ†æå’ŒéªŒè¯å¯¹åµå·¢è¡°è€ç›¸å…³åŸºå›  NDUFS5 å’Œ UBE2L3 è¿›è¡ŒåŠŸèƒ½è§£æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287822" target="_blank" rel="noopener noreferrer">GSE287822 ä¸¤ç§è·å¾—æ€§ç™«ç—«å¤§é¼ æ¨¡å‹ä¸­åŸºå› è¡¨è¾¾å’Œç”²åŸºåŒ–å˜åŒ–çš„å…±æ€§ [RRBS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281507" target="_blank" rel="noopener noreferrer">GSE281507 æ…¢æ€§è½»åº¦åº”æ¿€ä»¥æ€§åˆ«ä¾èµ–çš„æ–¹å¼æ”¹å˜ç»ˆçº¹å‰èƒŒä¾§æ ¸åºŠçš„è½¬å½•ç»„å’Œä¿¡å·ä¼ å¯¼ç‰¹æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263687" target="_blank" rel="noopener noreferrer">GSE263687 è¡°è€é€šè¿‡æ¿€æ´»æ•´åˆåº”æ¿€ååº”ä¿ƒè¿›è½¬ç§»ï¼ˆATAC-Seqï¼‰</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-23 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>